• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New | 134 studies released in batch on 2022-12-02
phs002520.v1.p1 | Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP): Community Based COVID-19 Testing Evaluation (study page |release notes )phs002521.v1.p1 | Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP): Creating a Sustainable Infrastructure for SARS-CoV-2 Testing at Syringe Exchange Programs (study page |release notes )phs002522.v1.p1 | Rapid Acceleration of Diagnostics - Radical (RADx-rad): MOF-SCENT: Metal-Organic Frameworks for Screening COVID-19 by Electronic-Nose Technology to Improve Selectivity and Time Response (study page |release notes )phs002523.v1.p...
Source: dbGaP, the database of Genotypes and Phenotypes - December 2, 2022 Category: Genetics & Stem Cells Tags: BatchStudyRelease Source Type: research

Johnson & Johnson and U.S. Department of Health & Human Services Expand Agreement to Support Next Phase of COVID-19 Vaccine Candidate Research and Development
NEW BRUNSWICK, N.J., November 14, 2020 – Johnson & Johnson (the Company) announced the expansion to the partnership between its Janssen Pharmaceutical Companies (Janssen) and the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services for the ongoing development of Janssen’s investigational COVID-19 vaccine candidate.Under the amendment, Janssen will commit approximately $604 million and BARDA will commit approximately $454 million to support the ongoing Phase 3 ENS...
Source: Johnson and Johnson - November 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

On Answering the Call to Action For COVID-19: Continuing a Bold Legacy of Health Advocacy.
Authors: Morgan RC, Reid TN Abstract The disproportionately high burden of death and disability observed for racial and ethnic minorities under the Coronavirus pandemic necessitates sustained advocacy by the medical and public health communities around critical determinants of population health. Prompting our advocacy should be the understanding that our collective ability to rebound from such crises may ultimately hinge on protecting and equipping our most vulnerable racial-ethnic minority groups and any susceptible individuals within those populations. If proven effective, recent historic firsts by the U.S. Depar...
Source: Journal of the National Medical Association - June 22, 2020 Category: General Medicine Tags: J Natl Med Assoc Source Type: research

Johnson and Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health and Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson Will Es... Biopharmaceuticals Johnson & Johnson, COVID-19, vaccine
Source: HSMN NewsFeed - March 30, 2020 Category: Pharmaceuticals Source Type: news